These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 19950316)

  • 41. [Tocilizumab in rheumatoid arthritis. Interleukin 6 as a new target].
    Heinzl S
    Med Monatsschr Pharm; 2008 Dec; 31(12):450-3. PubMed ID: 19133593
    [No Abstract]   [Full Text] [Related]  

  • 42. Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment.
    Nishida S; Hagihara K; Shima Y; Kawai M; Kuwahara Y; Arimitsu J; Hirano T; Narazaki M; Ogata A; Yoshizaki K; Kawase I; Kishimoto T; Tanaka T
    Ann Rheum Dis; 2009 Jul; 68(7):1235-6. PubMed ID: 19525413
    [No Abstract]   [Full Text] [Related]  

  • 43. Interleukin 6 receptor as a target for the treatment of rheumatoid arthritis.
    Choy E
    Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii68-9. PubMed ID: 14532153
    [No Abstract]   [Full Text] [Related]  

  • 44. [Clinical benefits of anti-human IL-6 receptor antibody therapy].
    Nishimoto N
    Clin Calcium; 2007 Apr; 17(4):562-8. PubMed ID: 17404486
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting the interleukin-6 receptor: a new treatment for systemic juvenile idiopathic arthritis?
    de Benedetti F; Martini A
    Arthritis Rheum; 2005 Mar; 52(3):687-93. PubMed ID: 15751082
    [No Abstract]   [Full Text] [Related]  

  • 46. Efficacy of tocilizumab and evaluation of clinical remission as determined by CDAI and MMP-3 level.
    Funahashi K; Koyano S; Miura T; Hagiwara T; Okuda K; Matsubara T
    Mod Rheumatol; 2009; 19(5):507-12. PubMed ID: 19609487
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis.
    Shima Y; Tomita T; Ishii T; Morishima A; Maeda Y; Ogata A; Kishimoto T; Tanaka T
    Mod Rheumatol; 2011 Aug; 21(4):436-9. PubMed ID: 21308388
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Hope for chronic inflammatory diseases : the anti-IL-6 receptor monoclonal antibody tocilizumab].
    Spertini F
    Rev Med Suisse; 2017 Jan; 13(544-545):20-22. PubMed ID: 28703529
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease.
    Kawabata H; Tomosugi N; Kanda J; Tanaka Y; Yoshizaki K; Uchiyama T
    Haematologica; 2007 Jun; 92(6):857-8. PubMed ID: 17550864
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tocilizumab in pediatric rheumatology: the clinical experience.
    Gurion R; Singer NG
    Curr Rheumatol Rep; 2013 Jul; 15(7):338. PubMed ID: 23715975
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Early treatment of reactive arthritis with etanercept and 2 years follow-up.
    Courcoul A; Muis Pistor O; Tebib JG; Coury F
    Joint Bone Spine; 2017 May; 84(3):367. PubMed ID: 27269651
    [No Abstract]   [Full Text] [Related]  

  • 52. Spectacular evolution of reactive arthritis after early treatment with infliximab.
    Thomas-Pohl M; Tissot A; Banal F; Lechevalier D
    Joint Bone Spine; 2012 Oct; 79(5):524. PubMed ID: 22542050
    [No Abstract]   [Full Text] [Related]  

  • 53. Failure of tocilizumab therapy in a patient with mouth and genital ulcers with inflamed cartilage syndrome complicated by aortic aneurysm.
    Terreaux W; Mestrallet S; Fauconier M; Pennaforte JL; Penalba C; Eschard JP; Salmon JH
    Rheumatology (Oxford); 2015 Nov; 54(11):2111-3. PubMed ID: 26175469
    [No Abstract]   [Full Text] [Related]  

  • 54. Interleukin 6 as therapeutic target in athero-/arteriosclerosis--small steps towards a new treatment paradigm in cardiovascular disease?
    Henry RM
    Atherosclerosis; 2011 Dec; 219(2):390-1. PubMed ID: 21840523
    [No Abstract]   [Full Text] [Related]  

  • 55. Development of a disease activity index for the assessment of reactive arthritis (DAREA).
    Eberl G; Studnicka-Benke A; Hitzelhammer H; Gschnait F; Smolen JS
    Rheumatology (Oxford); 2000 Feb; 39(2):148-55. PubMed ID: 10725064
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of subcutaneous tocilizumab in a patient with severe gout refractory to anakinra.
    Calvo-Aranda E; Sanchez-Aranda FM
    Rheumatology (Oxford); 2021 Nov; 60(11):e375-e377. PubMed ID: 34009241
    [No Abstract]   [Full Text] [Related]  

  • 57. An overview of reactive arthritis.
    Pennisi M; Perdue J; Roulston T; Nicholas J; Schmidt E; Rolfs J
    JAAPA; 2019 Jul; 32(7):25-28. PubMed ID: 31169570
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tocilizumab (Actemra) for giant cell arteritis.
    Med Lett Drugs Ther; 2017 Sep; 59(1530):161-162. PubMed ID: 28922343
    [No Abstract]   [Full Text] [Related]  

  • 59. Short-term effect of IL-6 inhibition in spondylarthritis.
    Wendling D; Bossert M; Prati C
    Joint Bone Spine; 2010 Dec; 77(6):624-5. PubMed ID: 20971669
    [No Abstract]   [Full Text] [Related]  

  • 60. Tocilizumab ameliorates clinical symptoms in polymyalgia rheumatica.
    Hagihara K; Kawase I; Tanaka T; Kishimoto T
    J Rheumatol; 2010 May; 37(5):1075-6. PubMed ID: 20439532
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.